ATS's Radiopharma Business Emerges as Key Growth Engine
Dow Jones
Sep 23
0809 ET - RBC says that while Life Sciences remains automation company ATS's primary focus, its radiopharma sub-segment, which covers diagnostics, therapeutics and radioisotopes, is emerging as an important growth driver. Analyst Sabahat Khan says in a note that ATS has historically been involved with diagnostics, and that isotope production automation is a near-term opportunity. Longer-term, Khan sees pharmaceutical automation for approved therapies--such as smaller batch, decentralized production requiring intense automation given the therapies are hazardous to operators--as a "potentially larger opportunity."
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.